Vimalanand S. Prabhu

Author

Merck & Co., Inc., Rahway, NJ, USA (United States)ORCID

Also Known As

Prabhu, Vimalanand, Prabhu, Vimalanand Shrikant, V Prabhu, V. Prabhu, V. S. Prabhu, V.S. Prabhu, Vimalanand Prabhu, Vimalanand S Prabhu, Vimalanand S. Prabhu, Vimalanand Shrikant Prabhu

100

Publications

1.5K

Citations

H-Index

Concepts

All Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)Centers for Disease Control and Prevention University of Washington Washington University in St. Louis Duke University

About

Vimalanand S. Prabhu is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, health economics, and preventive medicine.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	120
2	Public Health	2	2	68
3	Business	1	1	24
4	Engineering	1	1	24
5	Health Sciences	1	1	19

Vimalanand S. Prabhu

Publications

1.3K

Citations

H-Index

Page 1

	Year	Citations
Estimating the Burden of 2009 Pandemic Influenza A (H1N1) in the United States (April 2009-April 2010) Sundar S. Shrestha, David L. Swerdlow, Rebekah H. Borse, Clinical Infectious Diseases	2010	446
Epidemiological and economic burden of Clostridium difficile in the United States: estimates from a modeling approach Kamal Desai, Swati B. Gupta, Erik R. Dubberke, BMC Infectious Diseases	2016	155
Attributable Healthcare Resource Utilization and Costs for Patients With Primary and Recurrent Clostridium difficile Infection in the United States Dongmu Zhang, Vimalanand S. Prabhu, Stephen W. Marcella Clinical Infectious Diseases	2017	99
Cost-Effectiveness of Newborn Circumcision in Reducing Lifetime HIV Risk among U.S. Males Stephanie L. Sansom, Vimalanand S. Prabhu, Angela B. Hutchinson, PLoS ONE	2010	81
Cost-effectiveness of Bezlotoxumab Compared With Placebo for the Prevention of Recurrent Clostridium difficile Infection Vimalanand S. Prabhu, Erik R. Dubberke, Elamin H. Elbasha, Clinical Infectious Diseases	2017	66
Efficacy and safety over 26 weeks of an oral treatment strategy including sitagliptin compared with an injectable treatment strategy with liraglutide in patients with type 2 diabetes mellitus inadequately controlled on metformin: a randomised clinical trial B Charbonnel, H. Steinberg, E. Eymard, Diabetologia Diabetes ManagementMedicineDiabetesRandomised Clinical TrialType 2	2013	60
Cost-Effectiveness of Pooled Nucleic Acid Amplification Testing for Acute HIV Infection after Third-Generation HIV Antibody Screening and Rapid Testing in the United States: A Comparison of Three Public Health Settings Angela B. Hutchinson, Pragna Patel, Stephanie L. Sansom, PLoS Medicine	2010	59
Public health impact and cost-effectiveness of catch-up 9-valent HPV vaccination of individuals through age 45 years in the United States Vincent Daniels, Vimalanand S. Prabhu, Cody Palmer, Human Vaccines & Immunotherapeutics Population Health SciencesAdvisory CommitteeVaccine HesitancyUnited StatesPreventive Medicine	2021	47
Cost-Effectiveness of HIV Screening in STD Clinics, Emergency Departments, and Inpatient Units: A Model-Based Analysis Vimalanand S. Prabhu, Paul G. Farnham, Angela B. Hutchinson, PLoS ONE	2011	43
Cost-effectiveness of Pembrolizumab for Patients with Advanced, Unresectable, or Metastatic Urothelial Cancer Ineligible for Cisplatin-based Therapy K. Patterson, Vimalanand S. Prabhu, Ruifeng Xu, European Urology Oncology	2018	27

Page 1